Clinical trials
Solid Tumor Cancer clinical trials
Below are recruiting solid tumor cancer clinical trials, each written for real people, not researchers. We’re tracking 1,467 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05403554RecruitingPhase 1
Testing a new mesothelin-targeting drug for certain solid cancers
This Phase 1 study tests NI-1801, a drug designed to attach to a target on cancer cells (mesothelin). It may be given alone or with pembrolizumab to help shrink tumors in advanced cancers that have enough mesothelin on their cells.
ParisAges 18 years+ - NCT04693468RecruitingPhase 1
Testing three combinations for advanced solid tumors with gene defects
This Phase 1 trial tests whether adding specific medicines (talazoparib plus another drug) can help people with advanced or metastatic solid tumors that have certain gene or tumor marker changes. It also aims to find safer, workable doses and see how well these combinations work in different tumor groups.
Houston, TexasAges 18 years+ - NCT07719361RecruitingPhase 1
New drug for advanced, treatment-resistant prostate cancer
This study tests an experimental drug for men whose prostate cancer has spread and stopped responding to standard hormone therapies. It may be an option if your PSA is rising despite treatment with drugs like enzalutamide or abiraterone.
Los Angeles, CaliforniaAges 18 years+ - NCT05092373RecruitingPhase 1
Tumor treating device plus targeted or immune drugs for advanced cancers
This Phase 1 study tests whether a tumor treating fields device works better when added to standard cancer drugs. It may help people with advanced solid tumors in the chest or belly, especially when standard treatment didn’t work or can’t be tolerated.
Houston, TexasAges 18 years+ - NCT06514118Recruiting
Immunotherapy with radiation for advanced small-cell lung cancer
This trial tests a combination of chemotherapy, immunotherapy, and targeted radiation for people with extensive-stage small-cell lung cancer. The goal is to see if adding radiation to leftover tumors after initial treatment helps control the disease better.
Qingdao, ShandongAges 18–80 - NCT05947149Recruiting
Quality-of-life study in head and neck cancer after hadrontherapy
This study asks people with certain head and neck cancers (or long-term survivors) about how hadrontherapy affected their quality of life. It may help doctors understand long-term wellbeing and care needs after treatment.
Pavia, PvAges 18 years+ - NCT06606990RecruitingPhase 1
Testing the drug CX-5461 for advanced solid tumors
This trial tests a new drug called CX-5461 (also known as pidnarulex) in people whose cancer has spread and hasn't been helped by standard treatments. It looks at how your body responds to the drug, which may target cancers with specific DNA repair problems.
Bethesda, MarylandAges 18 years+ - NCT05779917RecruitingPhase 1
CAR-T cells for cancers that have specific target proteins
This Phase 1 trial tests a customized immune therapy (CAR-T cells) for advanced cancers that have the proteins mesothelin, GPC3, and/or GUCY2C. It may help your body better recognize and kill cancer cells, but early-phase trials mainly focus on safety and learning how well the treatment works.
Guangzhou, GuangdongAges 18–75 - NCT06839105RecruitingPhase 1
Testing AWT020 for advanced cancers
This study tests an experimental drug called AWT020 in people with advanced cancers that have either stopped responding to standard treatments or aren't candidates for them. The goal is to see if AWT020 is safe and tolerable across several cancer types such as lung cancer, melanoma, colorectal cancer, kidney cancer, and others.
Fuzhou, FujianAges 18 years+ - NCT06956690RecruitingPhase 1/Phase 2
Testing HMBD-501 for HER3-positive advanced solid tumors
This trial tests a new drug, HMBD-501, for people with advanced solid tumors that have a specific protein called HER3. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT05695638Recruiting
Genetic tumor testing to find treatments for advanced cancer
This study looks at your tumor’s genetic information to help match you to targeted treatments when standard options are no longer working. You may be offered options based on results, with the goal of helping people with incurable, worsening cancer.
AalborgAges 18 years+ - NCT06977737RecruitingPhase 1/Phase 2
Study of ATTR-01 for certain solid tumors
This trial tests a new treatment called ATTR-01 for people with certain types of solid tumors that have a specific protein (αvβ6 integrin) in high amounts. It is for those who have already tried standard treatments and need new options.
BarcelonaAges 18 years+ - NCT06297525RecruitingPhase 1
Testing STP938 for advanced solid tumors
This early-phase trial tests an experimental drug called STP938 (Dencatistat) for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if the drug is safe and how well it works against different cancer types.
St. Petersburg, FloridaAges 18 years+ - NCT06695689RecruitingEarly Phase 1
LM303 injection for advanced solid tumors
This trial tests an investigational treatment called LM303 for people with advanced solid tumors like melanoma, lung cancer, or cervical cancer. It uses your own immune cells (called TILs) to fight the cancer, so you need a tumor large enough for cells to be collected.
TianjinAges 18 years+ - NCT06697665RecruitingEarly Phase 1
LM103 vaccine with PD-1 for advanced solid tumors
This trial tests a new personalized cancer vaccine (LM103) combined with an immunotherapy drug (PD-1) for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if this combination is safe and can help shrink tumors.
China, Tianjin MunicipalityAges 18–75 - NCT07368127RecruitingPhase 1
Study of TPD3310 for advanced solid tumors
This trial tests an experimental drug called TPD3310 for people with advanced solid tumors (like lung, stomach, liver, or other cancers) that have worsened after standard treatments or cannot tolerate them. It aims to see if the drug is safe and works, especially for tumors with a specific marker called c-MET.
Beijing, Beijing MunicipalityAges 18–75 - NCT06717750RecruitingPhase 1
Study of a new drug for advanced solid tumors
This early-phase trial tests a new oral drug (CSCJC3456) for people with advanced solid tumors, especially those with certain FGFR gene changes. It aims to see if the drug is safe and may help when other treatments have stopped working.
Beijing, Beijing MunicipalityAges 18–75 - NCT07567222RecruitingPhase 1
Vaccine therapy for advanced solid tumors
This study tests a new therapeutic vaccine designed to help your immune system fight advanced solid cancers. You would receive vaccine injections alongside standard cancer care if your cancer has progressed despite previous treatments.
Chengdu, SichuanAges 18–75 - NCT06427941RecruitingPhase 1
Study of BGB-B2033 drug for advanced solid tumors
This trial tests a new drug, BGB-B2033, alone or with other treatments, for people with advanced liver, stomach, lung, or germ cell cancers that have not responded to standard therapy. The goal is to see if the drug is safe and works against these tumors.
Goodyear, ArizonaAges 18 years+ - NCT05272709RecruitingPhase 1/Phase 2
New pill TT-702 for advanced solid tumors
This trial tests a new pill called TT-702, either alone or with an immunotherapy drug, for people with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if it can help shrink or slow the growth of tumors.
LondonAges 16 years+ - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Birmingham, AlabamaAges 1–30 - NCT05604716Recruiting
Surgery Patients: Digestive and Social Function Follow-Up Study
This study checks how your digestion and daily social functioning may change after surgery. It looks at results from completed questionnaires filled out after your diagnosis to understand what issues patients face.
Beijing, Beijing MunicipalityAges Any age - NCT01137825Recruiting
Older patient cancer registry for a health check
This study is a registry that collects information from older adults who may be dealing with cancer. It includes a short health and function check to help doctors understand needs and guide care, even for people who turn out not to have cancer.
Boone, North CarolinaAges 65 years+ - NCT02421380Recruiting
Tests how repeatable a special MRI scan is for tumors
This study checks whether a specialized MRI using injected “hyperpolarized pyruvate” gives consistent tumor images when repeated. It may help future patients by improving how reliably this scan can measure tumors.
Montvale, New JerseyAges 21–90
Hear when a new Solid Tumor Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for solid tumor cancer?
- Yes. Clin2 currently lists 1,467 recruiting solid tumor cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a solid tumor cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a solid tumor cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.